Company Overview
Innate Pharma S.A. functions as a biotechnology firm dedicated to developing immunotherapies specifically for cancer patients within France and international markets. The company's primary product pipeline includes Lacutamab, designated as IPH4102, which is an anti-KIR3DL2 antibody currently undergoing Phase II clinical trials for the treatment of cutaneous T-cell and peripheral malignancies. Operating within the broader Healthcare sector and the specialized Biotechnology industry, the firm focuses on advancing novel therapeutic mechanisms to address oncology challenges. With a market capitalization of $126.41M and trailing twelve-month revenue of $9.01M, the company represents a mid-sized entity in the biotech landscape. These financial figures indicate that Innate Pharma is a capital-intensive business in an early-to-mid stage of commercialization, where significant value is derived from pipeline potential rather than established cash flow generation, reflecting the typical operational profile of biotechnology companies that are still navigating the regulatory and clinical development phases required before substantial profitability can be realized.
Financial Health
The company reported revenue of $9.01M over the trailing twelve months, yet posted a net income of -$49,177,000 and an EBITDA of -$52,625,000, revealing a substantial gap between top-line sales and bottom-line profitability. This disparity highlights a cost structure heavily weighted toward research and development expenses, which are standard for biotechnology firms but result in significant operating losses during the clinical trial phases. Free cash flow stands at -$38,315,624, indicating that the company is currently consuming cash to fund its operations and clinical programs rather than generating surplus liquidity. Despite these outflows, Innate Pharma holds $34.31M in cash against $22.57M in debt, suggesting a balance sheet that maintains liquidity coverage despite the absence of a debt-to-equity metric due to the company's capitalization structure. The current ratio is 1.27, which indicates that the company possesses sufficient current assets to cover its short-term liabilities, providing a buffer for ongoing operational needs. Margins reflect the pre-commercial nature of the business, with a gross margin of 100.0% typical of biotech manufacturing before variable costs, an operating margin of -689.6% driven by high fixed R&D costs, and a profit margin of 0.0% due to the net loss position. Return on assets is -38.8%, while return on equity is N/A, metrics that underscore the aggressive investment phase where management is prioritizing asset growth and pipeline advancement over immediate return generation.
Valuation Assessment
Valuation metrics for Innate Pharma present a complex picture due to the lack of traditional profitability measures, with a trailing P/E ratio of N/A and a forward P/E of -2.11. The negative forward P/E implies that analysts or market participants are projecting earnings that could turn positive in the future, or it reflects the mathematical artifact of current losses, suggesting that traditional earnings-based valuation is not currently applicable. The price-to-book ratio is -4.78, a figure that typically indicates negative equity or book value adjustments common in biotech firms with significant intangible assets that are not fully captured on the balance sheet, signaling a market premium or discount based on pipeline value rather than asset backing. Alternative metrics such as the price-to-sales ratio of 14.04 and an EV/EBITDA of -2.05 suggest that the market is pricing the stock primarily on revenue generation potential and sales growth trajectory rather than current earnings power. The stock trades between a 52-week high of $2.63 and a 52-week low of $1.17, and based on the provided data points, the current valuation sits within this volatility range, reflecting the speculative nature of the asset class. The beta value is N/A, meaning historical volatility relative to the broader market index is not quantifiable in the available data, which is common for small-cap biotech stocks that may have limited trading volume or recent listing history.
Growth & Income
Revenue growth over the past year stands at -46.7%, while earnings growth is N/A due to the absence of profitable earnings in the prior period for comparison. This contraction in revenue, coupled with the lack of positive earnings growth, implies that the company is facing headwinds in sales or is shifting resources heavily into new clinical programs that have not yet translated into commercial revenue. As a non-dividend payer, Innate Pharma reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that the company retains all available cash to reinvest into its research and development pipeline rather than distributing income to shareholders. The overall growth and income profile is characterized by negative revenue expansion and a complete absence of dividend income, reflecting the strategic choice of early-stage biotechnology companies to prioritize long-term product development and market penetration over short-term financial distribution.